Ex Vivo Mesenchymal Stem Cell Therapy to Regenerate Machine Perfused Organs

被引：16

作者：

Bogensperger, Christina ^{[1
,2
]}

Hofmann, Julia ^{[1
,2
]}

Messner, Franka ^{[1
,2
]}

Resch, Thomas ^{[1
,2
]}

Meszaros, Andras ^{[1
,2
]}

Cardini, Benno ^{[1
,2
]}

Weissenbacher, Annemarie ^{[1
,2
]}

Oberhuber, Rupert ^{[1
,2
]}

Troppmair, Jakob ^{[1
,2
]}

ofner, Dietmar ^{[1
,2
]}

Schneeberger, Stefan ^{[1
,2
]}

Hautz, Theresa ^{[1
]}

机构：

[1] Med Univ Innsbruck MUI, Dept Visceral Transplant & Thorac Surg VTT, Ctr Operat Med, Organ Life Lab, A-6020 Innsbruck, Austria

[2] Med Univ Innsbruck MUI, Daniel Swarovski Res Lab DSL, A-6020 Innsbruck, Austria

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 10期

关键词：

regeneration; mesenchymal stem cells; machine perfusion; INDUCED ACUTE LUNG; STROMAL CELLS; BONE-MARROW; RENAL-TRANSPLANTATION; COLD-STORAGE; LIVER-TRANSPLANTATION; REPERFUSION INJURY; DONOR HEARTS; OPEN-LABEL; T-CELLS;

D O I：

10.3390/ijms22105233

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Transplantation represents the treatment of choice for many end-stage diseases but is limited by the shortage of healthy donor organs. Ex situ normothermic machine perfusion (NMP) has the potential to extend the donor pool by facilitating the use of marginal quality organs such as those from donors after cardiac death (DCD) and extended criteria donors (ECD). NMP provides a platform for organ quality assessment but also offers the opportunity to treat and eventually regenerate organs during the perfusion process prior to transplantation. Due to their anti-inflammatory, immunomodulatory and regenerative capacity, mesenchymal stem cells (MSCs) are considered as an interesting tool in this model system. Only a limited number of studies have reported on the use of MSCs during ex situ machine perfusion so far with a focus on feasibility and safety aspects. At this point, no clinical benefits have been conclusively demonstrated, and studies with controlled transplantation set-ups are urgently warranted to elucidate favorable effects of MSCs in order to improve organs during ex situ machine perfusion.

引用

页数：15

共 109 条

[1] Allogeneic cell therapy manufacturing: process development technologies and facility design options [J].